AVI BioPharma Announces NEUGENE Antisense Collaboration With the Walter Reed Army Institute of Research.PORTLAND, Ore. -- AVI BioPharma, Inc. (Nasdaq:AVII), today announced it will be conducting collaborative research with the Walter Reed Army Institute of Research This article is about the U.S. Army medical research institute (not the hospital). Otherwise, see Walter Reed (disambiguation). The Walter Reed Army Institute of Research (WRAIR) is the largest biomedical research facility administered by the U.S. (WRAIR). The research, examining the effect of AVI's antisense agents against dengue and other flavivirus infections, is part of a Cooperative Research and Development Agreement “CRADA” redirects here. For other uses, see CRADA (disambiguation). A Cooperative Research and Development Agreement (CRADA) is an agreement between a government agency and a private company to work together. (CRADA) established with WRAIR as part of AVI's ongoing efforts in biodefense with the Chemical and Biological Defense Program of the Office of the Secretary of Defense The Office of the Secretary of Defense (OSD) is part of the United States Department of Defense and includes the entire staff of the Secretary of Defense. It is the principal staff element of the Secretary of Defense in the exercise of policy development, planning, resource . "Our previous work with the Department of Defense and its experience with our NEUGENE(R) technology led to the establishment of this formal relationship to pursue testing of our compounds against additional infectious agents," said Patrick L. Iversen, Ph.D., senior vice president of research and development at AVI. "We look forward to this collaboration, as it gives us yet another opportunity to expand the scope of application for our antisense technology." AVI believes its NEUGENE antisense "rapid response therapeutics" have a significant role to play in the future of antiviral therapeutics. NEUGENES are synthetic compounds that mirror a critical portion of a disease-causing organism's genetic code and bind to specific portions of the target genetic sequence. Like a key in a lock, NEUGENE antisense compounds are designed to match up precisely with a specific gene or viral sequence, blocking the function of the target gene or virus. About AVI BioPharma AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using two technology platforms: third-generation NEUGENE antisense drugs and cancer immunotherapy. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis, cancer and polycystic kidney disease Polycystic Kidney Disease Definition Polycystic kidney disease (PKD) is one of the most common of all life-threatening human genetic disorders. . In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to target single-stranded RNA viruses, including West Nile virus West Nile virus, microorganism and the infection resulting from it, which typically produces no symptoms or a flulike condition. The virus is a flavivirus and is related to a number of viruses that cause encephalitis. , SARS, coronavirus, hepatitis C virus
"Safe Harbor" Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion